Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 14 hours ago
- 2 min read
06/04/2026
Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 (Ref)
Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesity and cardiovascular disease (CVD), as well as multiple sclerosis (MS)
Primary outcome measures included the safety and tolerability of TNV262, as well as biomarkers of inflammation and cardiometabolic risk
Secondary outcome measures were designed to assess body weight and body composition, along with measures of appetite and eating behavior in persons with obesity
Tenvie expected to report preliminary safety and PK data in the H2 2026
Tenvie intended to initiate Phase 2 studies evaluating TNV262 in CVD and obesity, as well as in MS
Amgen announced topline results from Phase 3 teprotumumab in active TED (Ref)
Amgen announced positive topline results from a Phase 3 trial, which evaluated TEPEZZA (teprotumumab-trbw; target: IGF-1R) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED)
The Phase 3 trial met its primary endpoint, showing a statistically significant and clinically meaningful 77% proptosis response rate during the 24-week placebo-controlled period (76.7% TEPEZZA OBI vs. 19.6% placebo (p<0.0001))
A key secondary endpoint, the mean proptosis reduction, was -3.17 mm at week 24 (-3.17 mm TEPEZZA OBI vs. -0.80 mm placebo; p<0.0001)
The overall safety results were generally consistent with the known safety profile of TEPEZZA IV, mild-to-moderate injection site reactions were observed with SC administration in some patients, which did not result in treatment interruption or discontinuation
